Search Results

technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes

the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

She has advanced the use of computational methods to meet the challenges of designing therapeutics with

record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics

We hope our research will aid in the development of new therapeutic interventions for the alleviation

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic

Biased signalling of Class B G protein-coupled receptor-targeted therapeutics Read More April 1, 2025 proton-sensing GPCR Read More April 9, 2025 Molecular Dynamics (MD) Simulation of GPR87-LPA Binding: Therapeutic

Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

students, and industry professionals eager to deepen their knowledge of GPCR signaling, pharmacology, and therapeutic Terry Kenakin Development of GPCR Ligands and Therapeutic Drugs Up March 20 – April 10 4 weeks x 1 hour